3:54 PM
Jun 29, 2017
 |  BC Innovations  |  Translation in Brief


BioNTech creates cancer bispecifics from mRNA.

BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T cell-engaging antibodies (BiTEs) in cancer.

In June, the company published a study in Nature Medicine demonstrating RNA injection could produce functional levels of a bispecific antibody in mice with a better PK profile and less frequent dosing than its recombinant equivalent.

BioNTech COO Sean Marett told BioCentury the company will be initiating development programs for the RNA-encoded bispecific antibodies, dubbed RiboMABs. He said the platform should yield enough opportunities to partner some and keep others in house for development.

“We’ve been working with antibodies for years and it’s a real pain in the butt working on protein-based antibodies, just because of cell line development and manufacturing, standing in line to get some capacity with...

Read the full 739 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >